Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system

[1]  G. Marckmann,et al.  Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system , 2013, BMC Medical Ethics.

[2]  S. Schicktanz,et al.  What German experts expect from individualized medicine: problems of uncertainty and future complication in physician–patient interaction , 2012 .

[3]  Kelly Edwards,et al.  From patients to partners: participant-centric initiatives in biomedical research , 2012, Nature Reviews Genetics.

[4]  D. Lambrechts,et al.  Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet.

[5]  Sheryl Torr-Brown.  Regulatory and ethical challenges of personalized medicine. , 2010, Personalized medicine.

[6]  Ruth March,et al.  Delivering on the promise of personalized healthcare. , 2010, Personalized medicine.

[7]  L. Francis.  You are born with your genes: justice and protection against discrimination in the use of genetic information. , 2010, The Mount Sinai journal of medicine, New York.

[8]  Martin C. Müller,et al.  Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38) , 2010 .

[9]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2010, Leukemia.

[10]  L. Given.  The Sage encyclopedia of qualitative research methods , 2008 .

[11]  E. Bottinger,et al.  Foundations, promises and uncertainties of personalized medicine. , 2007, The Mount Sinai journal of medicine, New York.

[12]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[13]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[14]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[15]  W. Himmel,et al.  Pharmakogenetische Tests in der zukünftigen medizinischen Versorgung: Implikationen für Patienten und Ärzte , 2005 .

[16]  O. Corrigan,et al.  Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report , 2005, Journal of Medical Ethics.

[17]  M. Sutrop.  Pharmacogenetics: ethical issues. , 2004, Bioethics.

[18]  Andrew Smart,et al.  Tailored medicine: whom will it fit? The ethics of patient and disease stratification. , 2004, Bioethics.

[19]  W. Fierz.  Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends? , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[20]  David B Resnik,et al.  The precautionary principle and medical decision making. , 2004, The Journal of medicine and philosophy.

[21]  D W Nebert,et al.  Pharmacogenomics: out of the lab and into the community. , 2001, Trends in Biotechnology.

[22]  Michael Doherty,et al.  Pharmacogenetics--legal, ethical and regulatory considerations. , 2001, Pharmacogenomics.

[23]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[24]  Amalia M. Issa,et al.  Ethical considerations in clinical pharmacogenomics research. , 2000, Trends in pharmacological sciences.

[25]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.